menu

Improving Symptoms in Patients with HFrEF Using Novel Device Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Symptoms in Patients with HFrEF Using Novel Device Therapy

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Gurusher Panjrath explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Nirav Y. Raval, MD, FACC
    Director, Thoracic Transplant Programs
    AdventHealth Transplant Institute
    Orlando, Florida

    Nothing to disclose. 

    Faculty:
    Gurusher Panjrath, MD, FACC, FAHA, FHFSA
    Professor of Medicine, George Washington University School of Medicine and Health Sciences
    Director, Heart Failure and Mechanical Circulatory Support Program
    George Washington University Hospital
    Washington, DC

    Consulting Fees: CVRx, Pfizer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose. 
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Review the latest clinical data on the use of baroreflex activation therapy (BAT) in patients with heart failure, including durable and sustained benefits
    • Review patient selection criteria with respect to heart failure-related morbidity and mortality outcomes despite the use of guideline-directed medical therapy 
    • Describe the mechanism of action of BAT
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, cardiology advanced practice professionals, and other healthcare professionals who have an interest in treating heart failure.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CVRx.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Gurusher Panjrath explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Nirav Y. Raval, MD, FACC
    Director, Thoracic Transplant Programs
    AdventHealth Transplant Institute
    Orlando, Florida

    Nothing to disclose. 

    Faculty:
    Gurusher Panjrath, MD, FACC, FAHA, FHFSA
    Professor of Medicine, George Washington University School of Medicine and Health Sciences
    Director, Heart Failure and Mechanical Circulatory Support Program
    George Washington University Hospital
    Washington, DC

    Consulting Fees: CVRx, Pfizer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose. 
    • Howard Green has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Review the latest clinical data on the use of baroreflex activation therapy (BAT) in patients with heart failure, including durable and sustained benefits
    • Review patient selection criteria with respect to heart failure-related morbidity and mortality outcomes despite the use of guideline-directed medical therapy 
    • Describe the mechanism of action of BAT
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, cardiology advanced practice professionals, and other healthcare professionals who have an interest in treating heart failure.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CVRx.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Apr 2024